Resistance to Intervention: Paclitaxel in Breast Cancer

Abstract:: Breast cancer stands as the most prevalent cancer in women globally, and contributes to highest percentage in mortality to cancer related deaths in women. Paclitaxel (PTX) is heavily relied on as a frontline chemotherapy in breast cancer treatment, especially in advanced metastatic cancer. Generation of resistance to PTX often derails clinical management and adversely affects patient outcomes. Defining the molecular mechanism underlying PTX resistance is mostly sought for to aid in overcoming resistance, and this oriented research has led to the understanding of a range of PTX resistance related therapeutic targets. PTX resistance pathways that involve major regulatory proteins/RNAs like RNF8/Twist/ROR1, TLR, ErbB3/ErbB2, BRCA1-IRIS, MENA, LIN9, MiRNA, FoxM1 and IRAK1 have expanded the complexity of resistance mechanisms, and brought newer insights for development of drug targets. This resistance related targets can be dealt with synthetic/natural therapeutics in combination with PTX. The present review encompasses recent understanding of PTX resistance mechanisms in breast cancer and possible therapeutic combinations to overcome resistance.

Download Full-text

An Evaluation of Safety and Patient Outcomes for Hand Surgery following Prior Breast Cancer Treatment

Plastic & Reconstructive Surgery ◽

10.1097/prs.0000000000007006 ◽

2020 ◽

Vol 145 (5) ◽

pp. 1341

Keyword(s):

Breast Cancer ◽

Cancer Treatment ◽

Patient Outcomes ◽

Hand Surgery ◽

Breast Cancer Treatment

Download Full-text

Moving beyond PARP Inhibition: Current State and Future Perspectives in Breast Cancer

International Journal of Molecular Sciences ◽

10.3390/ijms22157884 ◽

2021 ◽

Vol 22 (15) ◽

pp. 7884

Author(s):

Michela Palleschi ◽

Gianluca Tedaldi ◽

Marianna Sirico ◽

Alessandra Virga ◽

Paola Ulivi ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Treatment ◽

Synthetic Lethality ◽

Current Knowledge ◽

Parp Inhibitors ◽

Resistance Mechanisms ◽

Breast Cancer Treatment ◽

Parp Inhibition ◽

Combination Strategies ◽

Pubmed Search

Breast cancer is the most frequent and lethal tumor in women and finding the best therapeutic strategy for each patient is an important challenge. PARP inhibitors (PARPis) are the first, clinically approved drugs designed to exploit synthetic lethality in tumors harboring BRCA1/2 mutations. Recent evidence indicates that PARPis have the potential to be used both in monotherapy and combination strategies in breast cancer treatment. In this review, we show the mechanism of action of PARPis and discuss the latest clinical applications in different breast cancer treatment settings, including the use as neoadjuvant and adjuvant approaches. Furthermore, as a class, PARPis show many similarities but also certain critical differences which can have essential clinical implications. Finally, we report the current knowledge about the resistance mechanisms to PARPis. A systematic PubMed search, using the entry terms “PARP inhibitors” and “breast cancer”, was performed to identify all published clinical trials (Phase I-II-III) and ongoing trials (ClinicalTrials.gov), that have been reported and discussed in this review.

Download Full-text

Tamoxifen resistance mechanisms in breast cancer treatment

World Journal of Advanced Research and Reviews ◽

10.30574/wjarr.2020.5.2.0429 ◽

2020 ◽

Vol 8 (2) ◽

pp. 224-232

Author(s):

Asima Tayyeb

Keyword(s):

Breast Cancer ◽

Cancer Treatment ◽

Molecular Mechanisms ◽

Tamoxifen Resistance ◽

Resistance Mechanisms ◽

Breast Cancer Treatment ◽

Therapeutic Interventions ◽

Survival Outcomes ◽

Breast Cancer Patients ◽

Current Review

Therapies targeting estrogen receptor (ER) are being widely used to treat ER+ breast cancer patients. Despite early detection and improved survival outcomes, tamoxifen resistance, either intrinsic or acquired- is a major obstacle in effective disease management. Current review will summarize different molecular mechanisms of tamoxifen resistance both intrinsic and acquired in breast cancer treatment. This review not only provides basis to understand the nature of tamoxifen drug resistance but also suggests the mechanisms for its control leading to improved therapeutic interventions.

Download Full-text